Loading clinical trials...
Loading clinical trials...
The aim of this study is to compare the overall tumour response rate per RECIST in postmenopausal women with metastatic or locally advanced breast cancer receiving AS1402 in combination with letrozole...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Antisoma Research
NCT06500481 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more
NCT07432633 · Colorectal Cancer, Epithelial Ovarian Cancer, and more
NCT06184750 · Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, and more
NCT04521764 · Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, and more
NCT05982496 · Breast Cancer Female, Lobular Breast Carcinoma, and more
State Medical Institution
Pyatigorsk, Stavropol Kray
State Therapeutical and Prophylactic Institution: Chelyabinsk Regional Oncological Center
Chelyabinsk
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions